Repligen (RGEN) Scheduled to Post Quarterly Earnings on Tuesday

Repligen (NASDAQ:RGEN) will announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of $0.34 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Repligen Stock Performance

NASDAQ:RGEN opened at $140.70 on Friday. The company has a market cap of $7.88 billion, a price-to-earnings ratio of -3,517.50, a PEG ratio of 4.19 and a beta of 0.96. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The stock’s 50 day simple moving average is $141.56 and its two-hundred day simple moving average is $145.21. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RGEN. JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Stephens restated an “overweight” rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.